Evidence map›Paper›PMID 27888688›Full record

ArticleBlood cells, molecules & diseases2017

An oral Hemokine

Douglas V Faller, Serguei A Castaneda, Daohong Zhou, Merriline Vedamony, Peter E Newburger, Gary L White, Stanley Kosanke, P Artur Plett, Christie M Orschell, Michael S Boosalis and 1 more

Open access · greenAbstract read
In one paragraph

Article in Blood cells, molecules & diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Douglas V FallerCancer Center, Boston University School of Medicine, Boston, MA, United States; Phoenicia BioSciences, Inc., Weston, MA, United States.
Serguei A CastanedaCancer Center, Boston University School of Medicine, Boston, MA, United States.
Daohong ZhouDivision of Radiation Health, Department of Pharmaceutical Sciences, University of Arkansas Medical School, Little Rock, AR, United States.
Merriline VedamonyArmed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Peter E NewburgerDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, MA, United States.
Gary L WhiteDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Stanley KosankeDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
P Artur PlettIndiana University, Indianapolis, IN, United States.
Christie M OrschellIndiana University, Indianapolis, IN, United States.
Michael S BoosalisCancer Center, Boston University School of Medicine, Boston, MA, United States.
Susan P PerrineCancer Center, Boston University School of Medicine, Boston, MA, United States; Phoenicia BioSciences, Inc., Weston, MA, United States. Electronic address: sperrine@bu.edu.
Boston University · USIndiana University – Purdue University Indianapolis · USPhoenicia Biosciences (United States) · USUniversity of Oklahoma Health Sciences Center · USArmed Forces Institute of Pathology · USUniversity of Massachusetts Chan Medical School · US

Funding

Baboon Research Resource ProgramP40OD010988 · OD · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BANKS, RON E · 2012 to 2018
$9.0M
RESEARCH TRAINING IN BLOOD DISEASES AND RESOURCEST32HL007501 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LERNER, ADAM, STEINBERG, MARTIN H. · 1985 to 2018
$5.4M
NOVEL GLOBIN GENE MODULATORSR01DK052962 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PERRINE, SUSAN PARK · 1998 to 2016
$4.2M
Multifaceted Interventions to Amplify HSC EngraftmentR01HL075660 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI ORSCHELL, CHRISTIE M · 2005 to 2009
$1.8M
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow InjuryR01AI080421 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI ZHOU, DAOHONG · 2008 to 2012
$1.8M
Oral Agents to Stimulate Neutrophil ProductionR41HL087542 · NHLBI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2010 to 2010
$351k
NHLBI NIH HHS R01 HL075660NHLBI NIH HHS R41 HL087542NHLBI NIH HHS T32 HL007501NIAID NIH HHS R01 AI080421NIDDK NIH HHS R01 DK052962NIH HHS P40 OD010988
6 · The paper itself

Abstract

An oral therapeutic which reduces duration of cytopenias and is active following accidental radiation exposures is an unmet need in radiation countermeasures. Alpha methylhydrocinnamate (ST7) prolongs STAT-5 phosphorylation, reduces growth-factor dependency of multi-lineage cell lines, and stimulates erythropoiesis. Here, ST7 and its isomers were studied for their effects on myeloid progenitors and hematopoietic stem cells (HSCs) following radiation, in nonhuman primates, and murine irradiation models. Addition of ST7 or ST7-S increased CFU-GM production by 1.7-fold (p<0.001), reduced neutrophil apoptosis comparable to G-CSF, and enhanced HSC survival post-radiation by 2-fold, (p=0.028). ST7 and ST7-S administered in normal baboons increased ANC and platelet counts by 50-400%. In sub-lethally-irradiated mice, ANC nadir remained >200/mm

Indexed as

AnimalsHematopoietic Stem CellsMiceMyeloid CellsNeutrophilsPapioPhenylpropionatesRadiation ExposureRecovery of FunctionSurvival RateWhole-Body Irradiationalpha-methylhydrocinnamic acidPhenylpropionates

Identifiers

PMID27888688
PMCPMC5458738
OpenAlexW2548080648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.